Condition: Focal Onset Seizures · Sponsor: Xenon Pharmaceuticals Inc.
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
This description comes directly from the study's public registry record.
Xenon Medical Affairs · 1-604-484-3300 · XenonCares@xenon-pharma.com
Always discuss trial participation with your own doctor first.
| Clinical Trials, Inc. | Little Rock, Arkansas, United States | Recruiting |
| Rancho Research Institute | Downey, California, United States | Recruiting |
| University of California Los Angeles (UCLA) | Los Angeles, California, United States | Recruiting |
| University of California Irvine Health | Orange, California, United States | Recruiting |
| Panhandle Research and Medical Clinic | Gulf Breeze, Florida, United States | Recruiting |
| Mayo Clinic Florida | Jacksonville, Florida, United States | Recruiting |
| Consultants in Epilepsy and Neurology, PLLC | Boise, Idaho, United States | Recruiting |
| Southern Illinois University School of Medicine | Springfield, Illinois, United States | Recruiting |
| Mid-Atlantic Epilepsy and Sleep Center | Bethesda, Maryland, United States | Recruiting |
| 9D University Health Center | Detroit, Michigan, United States | Recruiting |
| Northeast Regional Epilepsy Group | Hackensack, New Jersey, United States | Recruiting |
| Five Towns Neuroscience Research | Woodmere, New York, United States | Withdrawn |
+ 83 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05716100